





RealRate

PHARMACEUTICAL 2020

Blueprint Medicines Corp Rank 165 of 358



The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 25% points. The greatest weakness of Blueprint Medicines Corp is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 95%, being 58% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	516,786
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	106,482
Liabilities, Non-Current	136,853
Other Assets	152,547
Other Compr. Net Income	-2,354
Other Expenses	0
Other Liabilities	0
Other Net Income	13,632
Other Revenues	66,512
Property and Equipment	38,361
Research and Development	331,450
Selling, General and Administrative Expense	96,388

Output Variable	Value in 1000 USD
Assets	707,694
Liabilities	243,335
Expenses	427,838
Revenues	66,512
Stockholders Equity	464,359
Net Income	-347,694
Comprehensive Net Income	-348,871
Economic Capital Ratio	95%